[LCID Study Number: 2018-015]
A randomized, open label, phase 2 study to evaluate safety and efficacy of DUR -928 in subjects with primary Sclerosing Cholangitis (PSC)
The primary objectives are to evaluate the safety of DUR-928 in patients with PSC and to measure the change in alkaline phosphatase over the study period. Other liver enzymes will also be evaluated, but alkaline phosphatase is being used as a primary endpoint because it is the biomarker most frequently reported to be associated with quiescent or improving PSC symptoms.
Primary Contact Email: [email protected]
Primary Contact Phone: 781-744-3025